[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shirley Ryan AbilityLab\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":617},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,37,0,25,[9,56,85,109,130,151,175,196,224,253,278,297,324,351,377,402,422,441,466,486,512,533,552,569,593],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":4},"100643835","acute-intermittent-hypoxia-combined-with-gait-training-in-multiple-sclerosis-100643835",false,"NCT07631923","Acute Intermittent Hypoxia Combined With Gait Training in Multiple Sclerosis","Acute Intermittent Hypoxia (AIH) Primed Myoelectric Interface Neurorehabilitation Training (MINT) for Gait Recovery in Multiple Sclerosis","MINT","Inclusion Criteria:\n\n* Diagnosis of clinically definite multiple sclerosis\n* Patient-Determined Disease Steps (PDDS) score between 3 and 6\n* Relapse-free for at least 6 months prior to enrollment\n* Age ≥ 18 years and ≤ 75 years\n* Resting oxygen saturation (SpO₂) ≥ 95% on room air\n* Systolic blood pressure between 85-140 mmHg and diastolic blood pressure between 55-90 mmHg\n* Modified Ashworth Scale (MAS) score ≤ 3 at the ankle and knee\n* Mini-Mental State Examination (MMSE) score ≥ 24\n* Ability to walk at least 10 meters with or without an assistive device\n* Ability to perform active ankle dorsiflexion and plantarflexion\n\nExclusion Criteria:\n\n* Uncontrolled hypertension or hypotension outside the required ranges\n* History of epilepsy or seizures\n* Uncontrolled pulmonary, cardiovascular, or orthopedic disease\n* Premorbid or ongoing major psychiatric illness (e.g., major depression, psychosis)\n* Other neurological disease (e.g., stroke, traumatic brain injury, peripheral neuropathy)\n* Illnesses with potential to cause brain injury\n* Frequent or severe unexplained headaches\n* Pregnancy\n* Implanted medical devices (e.g., pacemakers, intrathecal pumps, brain stimulators)","ALL","18 Years","75 Years",{"count":22,"type":23},35,"ESTIMATED","INTERVENTIONAL",[26],"NA","This interventional, randomized, sham-controlled study will examine whether Acute Intermittent Hypoxia (AIH) delivered immediately before Myoelectric Interface Neurorehabilitation Training (MINT)-based locomotor training improves gait in people with Multiple Sclerosis. The primary objectives are to evaluate changes in gait speed and endurance, with secondary objectives assessing spatiotemporal gait parameters, fatigue, and safety. Participants will receive AIH or sham priming followed by standardized treadmill and\u002For overground gait training, with outcome measures collected before and after the intervention across multiple sessions.",[29,30,31,32],"Multiple Sclerosis","Multiple Sclerosis (MS) - Relapsing-remitting","Multiple Sclerosis (MS) Primary Progressive","Multiple Sclerosis (MS) Secondary Progressive",[34,35,36,37,38,39,40,41,42,43],"hypoxia","neuroplasticity","rehabilitation","gait","recovery","walking","walk","lower extremities","strength","AIH","NOT_YET_RECRUITING","2026-06-02",{"date":47,"type":48},"2026-06-08","ACTUAL",{"date":50,"type":23},"2026-06-15",{"date":52,"type":23},"2028-06-01",{"name":54,"class":55},"Shirley Ryan AbilityLab","OTHER",{"id":57,"slug":58,"hasResults":12,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":24,"phases":66,"briefSummary":69,"conditions":70,"keywords":72,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100581646","phase-1-double-dose-4-ap-on-functional-recovery-after-spinal-cord-injury-100581646","NCT06853015","Double Dose 4-AP on Functional Recovery After Spinal Cord Injury","Effects of Twice-daily Dosing 4-AP on Functional Recovery After Spinal Cord Injury","Inclusion Criteria:\n\n* Male and females between ages 18-85 years\n* SCI 6 months post injury\n* Spinal Cord injury at or above L2\n* ASIA A, B, C, or D, complete or incomplete\n* The ability to perform a small visible contraction with dorsiflexion and hip flexor muscles\n\nExclusion Criteria:\n\n* Uncontrolled medical problems including pulmonary, cardiovascular or orthopedic disease\n* Any history of renal impairment\n* Any debilitating disease prior to the SCI that caused exercise intolerance\n* Premorbid, ongoing major depression or psychosis, altered cognitive status\n* History of head injury or stroke\n* Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication\n* History of seizures or epilepsy\n* Receiving drugs acting primarily on the central nervous system, which lower the seizure threshold (see appendix 2)\n* Pregnant females\n* If a women of child bearing age is unsure of the pregnancy, and does not want to take the pregnancy test\n* Ongoing cord compression or a syrinx in the spinal cord or who suffer from a spinal cord disease such as spinal stenosis, spina bifida, MS, or herniated disk\n* Metal plate in skull\n* Individuals with scalp shrapnel, cochlear implants, or aneurysm clips\n* Individuals taking Bupropion, Dolutegravir, Lacosamide, Trilaciclib, or PR Interval prolonging drugs","85 Years",{"count":65,"type":23},27,[67,68],"PHASE1","PHASE2","The purpose of this study is to test a strategy to potentiate functional recovery of lower limb motor function in individuals with spinal cord injury (SCI). The FDA approved drug, Dalfampridine (4-AP). 4-AP will be used twice-daily in combination of Spike-timing-dependent plasticity (STDP) stimulation and STDP stimulation with limb training.",[71],"SCI - Spinal Cord Injury",[73,74,75,36],"spinal cord injury","neurostimulation","4-AP","RECRUITING",{"date":78,"type":48},"2026-06-03",{"date":80,"type":48},"2025-02-01",{"date":82,"type":23},"2026-12-30",{"name":54,"class":55},1,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":18,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":24,"phases":96,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":106,"leadSponsor":108,"locationsCount":84},"100626350","phase-2-smart-afo-and-5-azacitidine-to-enhance-mobility-in-children-with-cerebral-palsy-100626350","NCT07434492","Smart AFO and 5-Azacitidine to Enhance Mobility in Children With Cerebral Palsy","Smart Ankle-Foot Orthosis and 5-Azacitidine to Enhance Gait and Community Mobility for Children With Cerebral Palsy","Inclusion Criteria:\n\n* Diagnosis of cerebral palsy classified as Gross Motor Function Classification System (GMFCS) levels I to III\n* Between 8 and 17 years and 8 months of age at the time of enrollment\u002Fconsent. Participants that will turn 18 during the course of the study will not be included as pausing the at-home protocol until re-consenting is possible could interfere with intervention results.\n* Stable medical condition as determined by the investigator.\n* Adequate caregiver support to be able to participate in training and assessment sessions for the duration of the study, at the discretion of the PI.\n* Height\u002Fweight\u002FBMI between the 5th - 95th percentile of children with cerebral palsy\n* Able to walk for at least 6 minutes (assisted or unassisted)\n* Able to understand and follow simple directions\n* Able to safely fit into a device configuration and tolerate assistance without knee hyperextension while walking\n* At least 20 degrees of passive ankle plantar flexion range of motion\n* Physician approval for participation\n\nExclusion Criteria:\n\n* Knee extension or ankle dorsiflexion contractures greater than 15 degrees\n* Immunodeficiency or hematologic condition\n* Allergy to AZA or mannitol\n* Plans to receive a vaccine within 30 days of the planned AZA or placebo injection to take place at week 5\n* Pregnancy\n* Orthopedic surgery on the lower limbs completed in the prior 12 months\n* New implanted device (e.g., baclofen pump) and\u002For active intrathecal medication titration that may affect muscle spasticity\n* Botulinum toxin treatment within 3 months preceding enrollment unless given approval by the study physician\n* Severe osteoporosis unless given approval by the study physician\n* Current enrollment in a conflicting research study\n* Any other health condition or diagnosis not listed above that may put the participant at risk as determined by the PI or study physician","8 Years","17 Years",{"count":95,"type":23},60,[68],"This is an intervention study to investigate the impact of a smart ankle-foot orthosis (AFO) on mobility outcomes in children with Cerebral Palsy. Participants will complete a three phase protocol including 6-weeks of at home training with the smart AFO. Participants will also have the option to participate in a randomized control trial to investigate the impact of 5-Azacitidine combined with the smart AFO to further effect mobility outcomes.",[99],"Cerebral Palsy",[101],"Pediatric","2026-05-28",{"date":104,"type":48},"2026-06-01",{"date":102,"type":48},{"date":107,"type":23},"2030-08-31",{"name":54,"class":55},{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":12,"sex":18,"minAge":116,"maxAge":93,"enrollmentInfo":117,"targetDuration":4,"studyType":24,"phases":119,"briefSummary":120,"conditions":121,"keywords":122,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":129,"locationsCount":84},"100626237","phase-2-tscs-and-5-azacitidine-for-enhanced-motor-outcomes-in-cerebral-palsy-100626237","NCT07433023","tSCS and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy","Advancing Neurorehabilitation: Evaluating Transcutaneous Spinal Stimulation and 5-Azacitidine for Enhanced Motor Outcomes in Cerebral Palsy","Inclusion Criteria:\n\n* Diagnosis of cerebral palsy (CP) classified as Gross Motor Function Classification System (GMFCS) Levels I-V.\n* Between 4 and 17 years old at the time of enrollment\u002Fconsent.\n* Diagnosis of spastic CP hemiplegia, diplegia, or quadriplegia.\n* Stable medical condition as determined by the investigator.\n* Adequate caregiver support to be able to participate in training and assessment sessions for the duration of the study, at the discretion of the Investigator.\n* Capable of performing simple cued motor tasks and can follow 2-3 step commands.\n* Capable of communicating an accurate yes or no answer to questions according to parent or guardian.\n* Able to localize pain\u002F discomfort.\n* Physician approval for participation.\n* Parent\u002F guardian permission.\n\nExclusion Criteria:\n\n* Concurrent neurological disease affecting the central nervous system.\n* Cardiovascular or musculoskeletal disease or injury that would prevent full participation in physical therapy intervention\n* Orthopedic dysfunction, injury, or surgery that would impact an individual's ability to use the upper and\u002For lower extremity\n* Unhealed fracture or other musculoskeletal impairment that might interfere with upper or lower extremity rehabilitation or testing activities\n* Implanted stimulator (e.g., epidural stimulator, vagus nerve stimulator, pacemaker, cochlear implant) or drug delivery device (e.g., baclofen pump)\n* Dependence on an electro-magnetic medical implant (e.g., cardiac pacemaker, implanted drug pump), ventilation support, or another external device.\n* History of uncontrolled seizures\n* Unexplained presence of persistent complaints of pain of any kind\n* Unable to localize pain\u002Fdiscomfort\n* Severe cortico-visual impairment\n* Active pressure sores\n* Active urinary tract infection\n* Active cancer or cancer in remission less than 5 years\n* Clinically significant depression, psychiatric disorders, or ongoing drug abuse\n* Immunodeficiency or hematologic condition\n* Allergy to AZA or mannitol\n* Plans to receive a vaccine within 30 days of the planned AZA or placebo injection to take place at week 10\n* Pregnancy\n* Orthopedic surgery completed in the prior 12 months\n* Intrathecal medication titration that may affect muscle spasticity\n* Botulinum toxin treatment within 3 months preceding enrollment unless given approval by the treating physician\n* Current enrollment in a conflicting research study\n* Any other health condition or diagnosis not listed above that may put the participant at risk as determined by the investigator or treating physician","4 Years",{"count":118,"type":23},80,[68],"This is an intervention study to investigate the impact of spinal stimulation on mobility outcomes in children with Cerebral Palsy. Participants will complete a 16-week training program with weekly sessions of spinal stimulation and walking or activity-based training. Participants will also have the option to participate in a randomized control trial to investigate the impact of 5-Azacitidine combined with the spinal stimulation to further affect mobility outcomes.",[99],[101,123],"Transcutaneous Spinal Stimulation",{"date":125,"type":48},"2026-05-29",{"date":102,"type":48},{"date":128,"type":23},"2029-01-01",{"name":54,"class":55},{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":24,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":84},"100534076","characterization-and-clinical-trial-of-a-variable-friction-shoe-100534076","NCT06234124","Characterization and Clinical Trial of a Variable Friction Shoe","Characterization and Clinical Trial of a Variable Friction Shoe, a New Paradigm of Reduced-constraint Locomotor Therapy for People Exhibiting Foot Drop Due to Stroke","Inclusion Criteria:\n\n1. At least 3 months poststroke\n2. Age 18 or older\n3. Possess a prescribed AFO or be a potential candidate for use of an AFO\n4. Can ambulate at least 10m with or without an assistive device such as a cane or walker\n5. Medically stable as determined by physician medical clearance\n6. No expected change in medications for at least 3 months\n7. Adequate stability at the ankle during stance\n8. Ability to hear clicking noise made by the VF shoe\n9. Physician approval\n10. Ability to give informed consent\n11. Able to sit unsupported and be able to follow a three-step command\n12. No unhealed\u002Funresolved orthopedic injury to either upper or lower extremity and no history of severe back pain\n13. English speaking\n14. Willing to follow an exercise program with both devices for at least 30 minutes per day, at least 5 days per week for the full length of the program (6 months)\n\nExclusion Criteria:\n\n1. History of falling more than once a week prior to the stroke\n2. Gait speed: self-selected velocity (SSV) greater than 1.2 m\u002Fs\n3. Inability to operate in the devices safely and no caregiver assistance available\n4. Morbid obesity (body mass index \\>40 kg\u002Fm2)\n5. Preexisting conditions such as serious cardiac conditions, myocardial infarction, congestive heart failure, demand pacemaker, seizures, excessive dysesthetic pain, and severe lower extremity pathology that would interfere with fit or use of the shoe.\n6. Severe deficits in cognition or communication\n7. Pregnant women (status determined by self-reporting).\n8. Co-morbidity that interferes with the study (e.g. significant arthritis or joint problems, history of back injury, neuromuscular disorders, epilepsy, etc.).\n9. Severe Osteoporosis (status determined by self-reporting).\n10. Prisoners\n11. Not currently receiving botox to the lower extremities.",{"count":138,"type":23},50,[26],"More than one million Americans present with foot drop after stroke. As the aging population grows in the United States and across the world, incidence of stroke will grow as age is a key risk factor, thus there will be a need for low-cost, easy-to-use, and scalable solutions to administer proper therapy to promote recovery. This study will evaluate a Variable Friction shoe (VF shoe), a new low-cost medical device, for foot drop in an at-home setting.",[142],"Stroke","2026-05-07",{"date":145,"type":48},"2026-05-11",{"date":147,"type":48},"2024-04-03",{"date":149,"type":23},"2027-06",{"name":54,"class":55},{"id":152,"slug":153,"hasResults":12,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":4,"eligibilityCriteria":157,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":158,"enrollmentInfo":159,"targetDuration":4,"studyType":24,"phases":161,"briefSummary":162,"conditions":163,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":169,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":84},"100488777","nomad-p-kafo-study-100488777","NCT05644522","Nomad P-KAFO Study","Power Forward Study: A Cross-Sector, Multisite Clinical Trial of a Powered Knee-Ankle-Foot Orthosis","Inclusion Criteria:\n\n* Regular and compliant use of a unilateral or bilateral KAFO or SCO or other passive KAFOs for impairment due to neurological or neuromuscular disease, orthopedic disease, or trauma\n* Cognitive ability to understand and follow the study protocol; willingness to provide informed consent\n* Willing to wear and charge an activity monitor for three-months home trials.\n\nExclusion Criteria:\n\n* Flexion contracture in the knee and\u002For hip joint in excess of 15 degrees\n* Non-correctable knee varus\u002Fvalgus in excess of 15 degrees\n* Severe spasticity\n* Inability to stabilize the trunk with or without assistive devices (crutches, canes, etc.)","89 Years",{"count":160,"type":23},36,[26],"The goal of this clinical trial is to evaluate the impact of using the Nomad powered KAFO in people who have had a musculoskeletal or neurological injury that has affected their ability to walk. The main questions it aims to answer are to quantify the effectiveness of the Nomad in improving mobility, balance, frequency of falls, and quality of life in individuals with lower-extremity impairments compared to their own brace, over three months of daily home and community use.\n\nParticipants will:\n\n* Wear a sensor that records everyday activities and mobility.\n* Perform measures of mobility and different activities of participation using their own brace.\n* Perform measures of mobility and different activities of participation using the Nomad powered KAFO",[164,165,166,29,167,168],"Cerebrovascular Accident","Post-polio Syndrome","Spinal Cord Injuries","Muscular Dystrophy","Paralysis",{"date":145,"type":48},{"date":171,"type":48},"2024-03-01",{"date":173,"type":23},"2027-12",{"name":54,"class":55},{"id":176,"slug":177,"hasResults":12,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":182,"enrollmentInfo":183,"targetDuration":4,"studyType":24,"phases":184,"briefSummary":185,"conditions":186,"keywords":187,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":190,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":195,"locationsCount":84},"100471845","improving-adherence-to-spinal-cord-injury-exercise-guidelines-using-smartphone-technology-and-e-coaching-100471845","NCT05424172","Improving Adherence to Spinal Cord Injury Exercise Guidelines Using Smartphone Technology and E-coaching","Improving Adherence to Spinal Cord Injury Exercise Guidelines Using Smartphone-Based Technology and E-coaching: A Proof-of-Concept SMART-Design Study","Inclusion Criteria: Phase 1\n\n* Individual with diagnosis of SCI, formal or informal caregiver of an individual with an SCI, or clinician that regularly sees individuals with SCI\n* 18-80 years of age\n* English-speaking\n* Willing to download the study apps\n\nExclusion Criteria: Phase 1\n\n* Severe visual or cognitive problems that would affect the ability to complete the study\n* Does not own, or is unable to use a smartphone\n\nInclusion Criteria: Phase 2 and 3\n\n* Individual with diagnosis of SCI, complete (only paraplegia) or incomplete, cervical C3- C4 and below\n* 18-80 years of age\n* English-speaking\n* Use a wheelchair as primary means of mobility or walk with or without assistive equipment\n* At least 1-year post-SCI\n* Not adhering to SCI-specific exercise guidelines as ascertained by self-report or during structured phone interview\n* Interested in increasing exercise levels\n* Ownership of a smartphone that can be used for the study and has a data plan\n* Willing to successfully download and learn to use the study apps\n* Able and willing to give written consent and comply with study procedures, including multiple in person follow-up visits\n\nExclusion Criteria: Phase 2 and 3\n\n* Trauma or surgery in the past three months\n* An active stage 3 or 4 pressure ulcer\n* Medically unstable to perform the home-based exercise as determined by Dr. Chen and his team, the evaluating physical therapist, or the participants' primary care physician.\n* Unable to use at least one set of extremities to exercise\n* Enrolled in a structured exercise program over the past three months\n* Severe visual or cognitive problems that would affect the ability to complete the study\n* Does not own, or is unable to use a smartphone","80 Years",{"count":138,"type":23},[26],"The goal of this research is to increase physical activity among individuals with a spinal cord injury (SCI) through a customized, interactive smartphone-based health app and e-coaching using three phases: (1) leading focus groups of potential app users and clinicians to gain information regarding health apps preferences for optimal consumer use, (2) conducting a usability study of the customized app to determine the quality and implement further changes for optimization, and (3) conducting a sequential multiple assignment randomized trial (SMART) to determine the most effective adaptive intervention to improve exercise adherence. A SMART trial will be used to determine when and how to adapt dosage, timing, and delivery to increase adherence and address low-response behaviors. In Stage-I, the investigators will compare outcomes among participants using a generic, non-interactive exercise app (Group 1) to a customized, interactive app that can gain information through frequent Ecological Momentary Assessments (EMA) that will be used to modify each participant's exercise programs (Group 2). After 12 weeks, participants who are not meeting the exercise guidelines at least 50% of the time will also be asked to participate in motivational interviewing-based e-coaching either two or four times per month in addition to their originally assigned intervention (Stage-II). By completing these three phases, this project addresses deficiencies in exercise levels and compliance by implementing an individualized exercise prescription, an adaptive intervention for low responders, a way to address barriers to exercise, and a free smartphone app for broad implementation.",[166],[188,189],"Exercise","Telemedicine",{"date":145,"type":48},{"date":192,"type":48},"2022-11-02",{"date":194,"type":23},"2026-08-31",{"name":54,"class":55},{"id":197,"slug":198,"hasResults":12,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":203,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":204,"targetDuration":4,"studyType":24,"phases":205,"briefSummary":206,"conditions":207,"keywords":210,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":223,"locationsCount":84},"100624291","clinical-outcome-assessment-for-at--bci-100624291","NCT07407725","Clinical Outcome Assessment for AT & BCI","Development of a Clinical Outcome Assessment for Assistive Technologies and Brain-Computer-Interfaces","Enrollment will involve three different cohorts, namely a cohort of healthy participant, a cohort of ALS\u002FSCI participant who underwent the implant of an invasive BCI device, and a cohort of ALS\u002FSCI participants without any implanted BCI device.\n\nBelow are listed the inclusion and exclusion criteria for each diagnostic group.\n\nSpinal Cord Injury (SCI):\n\nInclusion Criteria:\n\n* Age at or above 18 years old;\n* Diagnosis of spinal cord injury, at the level of T1 or above levels (between C1 and T1);\n* Ability to communicate independently or with a support device, or with a legal representative;\n* Ability to participate in a study session for about 3 hours (e.g., endurance, fatigue), which may include breaks as needed.\n\nExclusion Criteria:\n\n* Participation in another trial that would conflict with the current study or clinical endpoint interference may occur.\n\nAmyotrophic Lateral Sclerosis (ALS):\n\nInclusion criteria:\n\n* Age at or above 18 years old;\n* Diagnosis of amyotrophic lateral sclerosis;\n* Ability to communicate independently, with a support device, or with a legal representative;\n* Ability to participate in a study session for about 3 hours (e.g., endurance, fatigue), which may include breaks as needed.\n\nExclusion criteria:\n\n● Participation in another trial that would conflict with the current study or clinical endpoint interference may occur.\n\nHealthy Controls:\n\nInclusion criteria:\n\n* Age at or above 18 years old;\n* No history of neurological or psychiatric disorders;\n* Ability to provide written informed consent;\n* Ability to participate in a study session for about 3 hours (e.g., endurance, fatigue), which may include breaks as needed.\n\nExclusion criteria:\n\n* Participation in another trial that would conflict with the current study or clinical endpoint interference may occur;\n* Cognitive, visual, or auditory deficits that would interfere with study participation;\n* Current or prior diagnosis or condition that could confound study assessments.",true,{"count":95,"type":23},[26],"Many individuals with severe motor impairments rely on Assistive Technologies (ATs) or Brain-Computer Interfaces (BCIs) to interact with digital devices such as their computers. Clinicians and researchers currently lack a common framework to objectively quantify how much a given AT or BCI improves real-world function or to compare across tools. This project seeks to address this gap by developing a standardized method to objectively assess or compare the functional benefit of these tools on digital independence, i.e., the ability to independently operate computers, phones, and other digital systems, by creating a unique Digital Assessment Interface (DAI).\n\nThis assessment will be a simulation of online and digital activities that prior work has determined is important to functional daily living in the digital domain. Participants will complete this assessment with various ATs and BCIs, and these scores will be used to create an index, which will be comprised of performance outcomes, clinician-reported outcomes, and patient-reported outcomes.\n\nThe tool aims to quantify and compare digital task performance across devices and user populations. The primary objective of this study is to develop an index. The index will quantify functional performance of individuals using various ATs and BCIs. The secondary objectives are to extensively evaluate the psychometric properties of the index, such as the validity, responsiveness, reliability, and floor\u002Fceiling effects both globally and across different devices and impairment levels, ensuring that it can reliably measure the impact of an AT or BCI on a user's ability to independently operate digital systems; and to characterize the familiarization and use of specific BCI and AT systems with reference to a normative healthy control population.",[208,209],"Spinal Cord Injury","ALS (Amyotrophic Lateral Sclerosis)",[211,212,213,214,215,216],"iBCI","Brain Computer Interface","Assistive Technology","Clinical Outcome Assessment","dADL","digital activities of daily living","2026-04-29",{"date":219,"type":48},"2026-05-05",{"date":221,"type":48},"2026-01-08",{"date":149,"type":23},{"name":54,"class":55},{"id":225,"slug":226,"hasResults":12,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":4,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":18,"minAge":231,"maxAge":232,"enrollmentInfo":233,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":236,"conditions":237,"keywords":241,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":244,"lastUpdatePostDateStruct":245,"startDateStruct":247,"completionDateStruct":249,"leadSponsor":251,"locationsCount":252},"100590676","wearable-sensors-to-detect-atypical-muscle-activation-in-young-infants-100590676","NCT06970522","Wearable Sensors to Detect Atypical Muscle Activation in Young Infants","Early Detection of Atypical Neuromuscular Development Using Wearable Sensors and Video: A Comparative Analysis of Muscle and Motion","Inclusion Criteria:\n\n* For Infants with low tone:\n* Hospitalized in the NICU\n* AND \\>38 weeks post-menstrual age\n* AND abnormal normal brain imaging OR Apgar score \\\u003C7 at five minutes with umbilical cord pH (if obtained) \\\u003C7.15\n* AND 2 or more warning signs for muscle tone or posture using the HNNE short form\n* AND legal guardian able and willing to give written consent and comply with study procedures\n* For Infants with typical tone:\n* Born at 38-41 weeks of gestation\n* AND hospitalized after birth in the NICU OR well newborn nursery\n* AND infants with appropriate for gestational age birth weight\n* AND HNNE exam (short proforma) normal with no warning signs for any parameter\n* AND legal guardian able and willing to give written consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Infants of Both Low Tone and Typical Tone Cohorts:\n* Missing or incomplete limbs (such as from amputation or congenital limb defects).\n* Open wounds or skin breakdown on the limbs or torso.\n* Presence of known genetic syndrome or congenital anomalies requiring surgery or affecting function\n* Use of sedative medications (may include phenobarbital if level stable and therapeutic)\n* Legal guardian unable to give written consent and comply with study procedures.\n* Does not receive medical clearance from a physician to participate in the study if the individual is receiving inpatient care.","0 Months","8 Weeks",{"count":234,"type":23},40,"OBSERVATIONAL","The purpose of this study is to see if wearable sensor technology can be used to evaluate muscle activity and\u002For identify atypical muscle tone in infants up to 48 weeks postmenstrual age (8 weeks corrected age). These sensors are placed on the surface of the skin and record data about a child's body movements and muscle activity.",[238,239,240],"Neuromuscular Disorders","Motor Development","Muscle Tone",[242,243],"Early Detection","Wearable Sensors","2026-03-24",{"date":246,"type":48},"2026-03-25",{"date":248,"type":48},"2025-06-25",{"date":250,"type":23},"2026-12-31",{"name":54,"class":55},2,{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":260,"targetDuration":4,"studyType":24,"phases":262,"briefSummary":263,"conditions":264,"keywords":267,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":84},"100537346","intermittent-hypoxia-in-persons-with-multiple-sclerosis-100537346","NCT06276634","Intermittent Hypoxia in Persons With Multiple Sclerosis","Intermittent Hypoxia Initiated Motor Plasticity in Individuals With Multiple Sclerosis","Inclusion Criteria:\n\n* Diagnoses of relapsing form of MS (including relapsing-remitting MS and secondary-progressive MS)\n* Expanded Disability Status Scale (EDSS) score of at least 3 and no more than 6.5\n* Motor Functional System Scale (FSS) between 2-4\n* Relapse free for at least 1 year\n* Age ≥ 18 years and ≤ 75 years\n* Safe to be scanned based on MRI questionnaire\n* Participants using dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening\n\nExclusion Criteria:\n\n* Active contrast-enhancing MS lesions, or diffusion positive lesions suggestive of acute cerebrovascular disease on baseline MRI scan\n* Uncontrolled hypertension (Systolic between 85 and 140, diastolic between 90 and 55)\n* History of epilepsy\n* Chronic obstructive pulmonary disease\n* Uncontrolled Sleep apnea\n* Pregnancy",{"count":261,"type":23},21,[26],"This study aims to understand the mechanisms of a novel intervention involving breathing short durations of low levels of oxygen for persons with multiple sclerosis (MS). This intervention with low levels of oxygen is called Acute Intermittent Hypoxia (AIH), the levels of oxygen experienced are similar to breathing the air on a tall mountain, for less than 1 minute at a time. Previous studies have shown that AIH is a safe and effective way to increase strength in persons with MS. Here the investigators aim to look at brain activation and ankle strength before and after AIH to gain a better understanding of how the AIH may improve strength in those persons with MS.",[29,265,266],"Multiple Sclerosis-Relapsing-Remitting","Multiple Sclerosis, Secondary Progressive",[268,43,269],"multiple sclerosis","Hypoxia","2026-03-18",{"date":272,"type":48},"2026-03-20",{"date":274,"type":48},"2024-04-30",{"date":276,"type":23},"2027-01",{"name":54,"class":55},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":284,"targetDuration":4,"studyType":24,"phases":286,"briefSummary":287,"conditions":288,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":289,"lastUpdatePostDateStruct":290,"startDateStruct":292,"completionDateStruct":294,"leadSponsor":296,"locationsCount":84},"100452152","locomotor-function-following-transcutaneous-electrical-spinal-cord-stimulation-in-individuals-with-hemiplegic-stroke-100452152","NCT05167786","Locomotor Function Following Transcutaneous Electrical Spinal Cord Stimulation in Individuals With Hemiplegic Stroke","Inclusion Criteria\n\n* Age 18 years or older\n* Able and willing to give written consent and comply with study procedures\n* At least 6 months' post-stroke\n* Hemiplegia secondary to a single stroke\n* Functional Ambulation Category of 2 or greater - i.e., subject needs continuous or intermittent support of one person to help with balance and coordination.\n* Not currently receiving regular physical therapy services\n* Physician approval to participate\n\nExclusion Criteria\n\n* Ataxia\n* Multiple stroke history\n* Botox injection in lower extremity within the last 4 months\n* Modified Ashworth score of 3 or greater in lower extremity\n* Pregnant or nursing\n* Using a powered, implanted cardiac device for monitoring or support of heart function (i.e. pacemaker, defibrillator, or LVAD) or anti-spasticity implantable pumps\n* Active pressure sores\n* Unhealed bone fractures\n* Peripheral neuropathies\n* Painful musculoskeletal dysfunction due to active injuries or infections\n* Severe contractures in the lower extremities\n* Medical illness limiting the ability to walk\n* Active urinary tract infection\n* Clinically significant depression, psychiatric disorders, or ongoing drug abuse\n* Active cancer or cancer in remission less than 5 years\n* Orthopedic dysfunction, injury, or surgery that would impact an individual's ability to use the lower extremity.\n* Traumatic brain injury or other neurological conditions that would impact the study.\n\nTMS-Specific Exclusion Criteria: TMS will be utilized for both Aims. The sub-set of participants who meet these criteria will participate in this component of the studies.\n\n* Medicated with agents known to increase (e.g., amphetamines) or decrease motor system excitability (e.g., lorazepam)\n* Implanted cardiac pacemaker\n* Metal implants in the head or face\n* Suffers unexplained, recurring headaches\n* Had a seizure in the past unrelated to the stroke event, or has epilepsy\n* Skull abnormalities or fractures\n* A concussion within the last 6 months\n* Unstable cardiorespiratory or metabolic diseases (e.g. cardiac arrhythmia, uncontrolled hypertension, uncontrolled diabetes, or chronic emphysema)",{"count":285,"type":23},115,[26],"This study has two interventional components, the first is a cross-over design and the second is a randomized control trial. Both will evaluate the effectiveness of transcutaneous (non-invasive) spinal cord stimulation on gait and balance function for individuals with hemiplegia due to stroke.",[142],"2026-03-13",{"date":291,"type":48},"2026-03-17",{"date":293,"type":48},"2022-03-01",{"date":295,"type":23},"2027-07-31",{"name":54,"class":55},{"id":298,"slug":299,"hasResults":12,"nctId":300,"briefTitle":301,"officialTitle":302,"acronym":4,"eligibilityCriteria":303,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":304,"targetDuration":4,"studyType":24,"phases":306,"briefSummary":307,"conditions":308,"keywords":310,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":317,"lastUpdatePostDateStruct":318,"startDateStruct":320,"completionDateStruct":321,"leadSponsor":323,"locationsCount":84},"100546130","effects-of-acute-intermittent-hypoxia-on-neuroplasticity-in-ms-100546130","NCT06390930","Effects of Acute Intermittent Hypoxia on Neuroplasticity in MS","Investigating the Effects of Acute Intermittent Hypoxia on Neuroplasticity in Persons With Multiple Sclerosis","Inclusion Criteria:\n\n* Diagnosis of relapsing-remitting MS according to the McDonald criteria, over 5 years ago\n* Relapse free for at least 6 months\n* Expanded Disability Status Scale (EDSS) ≤7\n* Index finger abduction strength \\\u003C5 according to Medical Research Council Scale, or 9-Hole Peg Test score \\>20 seconds in at least one hand\n* Stable disease modifying therapies for at least 6 months\n* Individuals taking dalfampridine will be eligible if taking the same daily dose for at least 2 months prior to screening\n\nExclusion Criteria:\n\n* Another diagnosis (e.g., peripheral neuropathies or orthopedic) affecting upper limb function\n* Mini-Mental State Examination (MMSE) score \\\u003C24\n* Modified Ashworth Scale score \\>3 on elbow joint\n* Uncontrolled hypertension or hypotension (outside 140\u002F90 and 85\u002F55 mmHg)\n* History of epilepsy, chronic obstructive pulmonary disease, or sleep apnea\n* Unstable medical conditions, ongoing upper limb therapy, or musculoskeletal pain\n* Pregnancy as confirmed by urine test",{"count":305,"type":23},22,[26],"This study seeks to explore changes in the neural pathways and arm function following a breathing intervention in the multiple sclerosis (MS) population. The breathing intervention, known as Acute Intermittent Hypoxia (AIH), involves breathing brief bouts of low levels of oxygen. Research has found AIH to be a safe and effective intervention resulting in increased ankle strength in people with MS. Here, the study examines arm and hand function before and after AIH. In order to better understand the brain and spinal cord response to AIH, the investigators will measure muscle response, and signals sent from the brain to the arm muscles before and after AIH.",[29,309,266],"Multiple Sclerosis, Relapsing-Remitting",[268,311,35,312,313,34,314,315,316],"plasticity","motoneuron","aih","Acute Intermittent Hypoxia","arm","upper extremity","2026-02-19",{"date":319,"type":48},"2026-02-23",{"date":80,"type":48},{"date":322,"type":23},"2027-07",{"name":54,"class":55},{"id":325,"slug":326,"hasResults":12,"nctId":327,"briefTitle":328,"officialTitle":329,"acronym":4,"eligibilityCriteria":330,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":331,"targetDuration":4,"studyType":24,"phases":333,"briefSummary":334,"conditions":335,"keywords":338,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":350},"100620988","enhancing-rehabilitation-participation-in-patients-with-scid-using-motivational-interviewing-100620988","NCT07364773","Enhancing Rehabilitation Participation in Patients With SCI\u002FD Using Motivational Interviewing","Enhancing Rehabilitation Participation in Patients With Spinal Cord Injury or Disorder Using Motivational Interviewing","Therapist Inclusion Criteria:\n\n* Inpatient therapist specializing in spinal cord injury patients for at least 3 months;\n* Practicing at the designated SCI inpatient units at Shirley Ryan AbilityLab, Baylor Scott \\& White Institute for Rehabilitation and University of Washington-Harborview Medical Center;\n* Willing to audio record conversations during regularly-scheduled rehabilitation therapy sessions with patients;\n* Willing and able to participate in 16 hours of MI training; and\n* Willing to receive feedback on MI skills.\n\nTherapist Exclusion Criteria:\n\n* Inability to speak and understand English\n* Inpatient therapist specializing in spinal cord injury patients for less than 3 months; and\n* Unwilling or unable to follow the study protocol\n\nPatient Inclusion Criteria:\n\n* Adults (18+)\n* Presence of a traumatic or non-traumatic spinal cord injury\n* Inpatient in the spinal cord injury unit of the three study sites\n* Has a physical or occupational therapist who is a participant in the study\n\nPatient Exclusion Criteria:\n\n* Inability to speak and understand English\n* Cognitive deficits\n* Unwilling to allow for therapy sessions to be recorded",{"count":332,"type":23},180,[26],"The purpose of this multi-site clinical trial is to see whether people with spinal cord injury or disorder (SCI\u002FD) demonstrate higher level of participation in rehabilitation sessions and other outcomes when their therapists are trained in a counseling style called motivational interviewing. We want to answer the following questions:\n\n1. Do inpatients with SCI\u002FD treated by physical therapists (PTs) and occupational therapists (OTs) who receive MI training and coaching demonstrate greater therapy participation compared to those treated by therapists who do not receive MI training and coaching?\n2. Do inpatients with SCI\u002FD treated by PTs and OTs who receive MI training and coaching demonstrate greater functional improvement at discharge from inpatient rehabilitation and greater community integration at 6 months after discharge compared to those treated by therapists who do not receive MI training and coaching?\n3. What are the potential moderators and mediators of the effect of training and coaching on MI skills on therapy participation?\n\nResearchers will compare patient participation level and other outcomes of inpatients with SCI\u002FD treated by PTs and OTs who receive MI training and coaching with those treated by therapists who do not receive MI training and coaching.\n\nTherapist participants will:\n\n1. Audio record 2 therapy sessions per week with each enrolled SCI patient participant\n2. Half of the therapists will attend a 16-hour training on MI skills and 2 practice therapy session\n\nPatient participants will:\n\n1. Consent to audio recording of their therapy sessions\n2. Complete one brief survey near the time of their discharge and another survey 6 months later",[336,337],"Spinal Cord Injuries (SCI)","Spinal Cord Disease",[208,339,340,341],"Spinal Cord Disorder","Motivational Interviewing","Rehabilitation","2026-01-16",{"date":344,"type":48},"2026-01-23",{"date":346,"type":48},"2025-11-01",{"date":348,"type":23},"2027-04-20",{"name":54,"class":55},3,{"id":352,"slug":353,"hasResults":12,"nctId":354,"briefTitle":355,"officialTitle":356,"acronym":4,"eligibilityCriteria":357,"healthyVolunteers":203,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":358,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":360,"conditions":361,"keywords":362,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":369,"lastUpdatePostDateStruct":370,"startDateStruct":372,"completionDateStruct":374,"leadSponsor":376,"locationsCount":84},"100379368","inpatient-stroke-recovery-using-sensors-100379368","NCT04219670","Inpatient Stroke Recovery Using Sensors","Wearable Sensor Platform to Monitor Stroke Recovery During Inpatient Rehabilitation","Inclusion Criteria:\n\n* Patient group\n\n  * Individuals diagnosed with stroke admitted to the Shirley Ryan AbilityLab (inpatient), or individuals in the community who had a stroke (chronic)\n  * Age 18 or older\n  * Able and willing to give written consent and comply with study procedures\n* Healthy control group\n\n  * Individuals without any known significant health problem (healthy controls)\n  * Age 18 or older\n  * Able and willing to give written consent and comply with study procedures\n\nExclusion Criteria:\n\n* Patient group\n\n  * Neurological degenerative pathologies as co-morbidities (such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, etc.)\n  * Pregnant or nursing\n  * Skin allergies or irritation; open wounds\n  * Utilizing a powered, implanted cardiac device for monitoring or supporting heart function (i.e. pacemaker, defibrillator, or LVAD)\n* Healthy control group\n\n  * No known history of cerebrovascular accidents or neurological degenerative pathologies (such as multiple sclerosis, Alzheimer's disease, Parkinson's disease, etc.)\n  * Pregnant or nursing\n  * Skin allergies or irritation; open wounds\n  * Utilizing a powered, implanted cardiac device for monitoring or supporting heart function (i.e. pacemaker, defibrillator, or LVAD)",{"count":359,"type":23},400,"This observational trial seeks to assess the feasibility of using non-invasive, portable, real-time body-worn sensors to continuously monitor, quantify, and interpret recovery during inpatient treatment of stroke",[142],[142,363,364,365,366,367,368],"Device Studies","Noninvasive Procedures","Device Feasibility","Inpatient Rehabilitation","Sensors","Machine Learning","2025-12-19",{"date":371,"type":48},"2025-12-29",{"date":373,"type":48},"2017-10-31",{"date":375,"type":23},"2026-12",{"name":54,"class":55},{"id":378,"slug":379,"hasResults":12,"nctId":380,"briefTitle":381,"officialTitle":382,"acronym":4,"eligibilityCriteria":383,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":384,"targetDuration":4,"studyType":24,"phases":386,"briefSummary":387,"conditions":388,"keywords":389,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":394,"lastUpdatePostDateStruct":395,"startDateStruct":397,"completionDateStruct":399,"leadSponsor":401,"locationsCount":84},"100610140","phase-1-improving-walking-after-spinal-cord-injury-100610140","NCT07223710","Improving Walking After Spinal Cord Injury","Engaging Reticulospinal Inputs to Improve Walking Ability in Humans With Spinal Cord Injury","Inclusion Criteria:\n\n* History of traumatic or non-traumatic SCI ≥ 6 months\n* International Standards for Neurological Classification of Spinal Cord Injury (ISNCSCI) level at and above T10.\n* American Spinal Injury Association AIS Grade C, or D\n* Weakness in ankle dorsiflexors (LEMS\\\u003C=3) with the ability to perform a small voluntary ankle dorsiflexion (as detected by presence of voluntary EMG activity in the tibialis anterior) with at least one leg.\n* Ability to tolerate standing position.\n* Ability to walk at a minimum speed of 0.1 mile\u002Fhour on a treadmill with less than 70% body weight support.\n* Requires use of assistive devices (KAFO, AFO, cane, walker) or body weight support for ambulation.\n* Ability to complete the 10-Meter Walk Test.\n\nExclusion Criteria:\n\n* Preceding uncontrolled medical conditions including pulmonary, cardiovascular or orthopedic disease that interfere with physical performance.\n* Intolerance to physical activity.\n* Severe cognitive impairment that precludes the ability to participate in any of the study procedures or give verbal consent.\n* Any illness or condition that based on the research team's assessment, will compromise with the patient's ability to comply with the protocol, patient safety, or the validity of the data collected during the study.\n* History of stroke resulting in sensory motor deficits.\n* Pregnant women.\n* Participation in a high-intensity locomotor training program in the last 6 months.\n* Inability to detect somatosensory evoked potentials\n* Metal implant in the head\n* History of epilepsy",{"count":385,"type":23},20,[67,68],"Locomotor recovery is one of the most important goals of individuals with spinal cord injury (SCI). Ambulatory deficits severely impact daily functions resulting in lower quality of life for people living with paralysis due to SCI. Although studies have shown that locomotor training improves locomotor function in people with chronic SCI, the benefits remain limited. Our overall hypothesis is that we can engage additional descending motor pathways, such as the reticulospinal tract (RST), to improve locomotor function in humans with chronic incomplete SCI.\n\nIn this study we propose to test the effects of a novel intervention that uses repeated paired loud auditory and electrical stimulation of muscle afferents combined with locomotor training on walking speed and voluntary muscle strength.",[208],[390,391,392,393],"auditory stimulation","peripheral stimulation","locomotion training","descending motor tracts","2025-10-30",{"date":396,"type":48},"2025-11-03",{"date":398,"type":23},"2025-11-15",{"date":400,"type":23},"2026-07-30",{"name":54,"class":55},{"id":403,"slug":404,"hasResults":12,"nctId":405,"briefTitle":406,"officialTitle":406,"acronym":4,"eligibilityCriteria":407,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":408,"targetDuration":4,"studyType":24,"phases":410,"briefSummary":411,"conditions":412,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":415,"lastUpdatePostDateStruct":416,"startDateStruct":418,"completionDateStruct":420,"leadSponsor":421,"locationsCount":84},"100603150","evaluation-of-the-safety-and-efficacy-of-a-full-body-electrostimulation-garment-for-individuals-with-neurological-and-neuromuscular-conditions-that-cause-spasticity-hyperreflexia-and-pain-100603150","NCT07132775","Evaluation of the Safety and Efficacy of a Full-Body Electrostimulation Garment for Individuals With Neurological and Neuromuscular Conditions That Cause Spasticity, Hyperreflexia, and Pain","Inclusion Criteria:\n\n1. Age 18 to 75 years old\n2. Medical clearance from physician\n3. Individuals who experience spasticity, pain, or hyperreflexia due to neurological or neuromuscular conditions or individuals with a diagnosis of Multiple Sclerosis or Fibromyalgia\n4. For participants with a diagnosis of Multiple Sclerosis:\n\n   1. having a definite diagnosis for at least one month\n   2. Ability to walk independently or with the need of support (expanded disability status scale score (EDSS) \\\u003C 7).\n   3. Absence of relapses in the last three months\n   4. Demonstrating spasticity with a score of at least 1+ on the Modified Ashworth Scale (MAS)\n   5. Berg Balance Scale (BBS) score of \\\u003C 46 (associated in the literature with a risk of fall)\n5. For participants with a diagnosis of Fibromyalgia:\n\n   a. having a definite diagnosis for at least three months\n6. Able to follow instructions and inform study staff of pain and\u002For discomfort\n7. Able to ambulate 10m without body weight support with or without assistive devices and\u002For caregiver assistance\n\nExclusion Criteria:\n\n1. Implanted medical devices or equipment which can be disrupted by magnets (ex. Shunts)\n2. Swollen, infected, or inflamed areas or skin eruptions (e.g., phlebitis, thrombophlebitis, varicose veins, etc.) in areas where the suit will be used\n3. No established somatic or neuropsychiatric diagnosis prior to enrollment in the study\n4. Pregnant and\u002For nursing",{"count":409,"type":23},15,[26],"The purpose of this study is to to explore the safety and efficacy of the EXOPULSE Mollii suit, a full-body electrostimulation suit, for individuals with neurological or neuromuscular conditions that cause spasticity, hyperreflexia, and\u002For pain.",[29,413,414,238],"Fibromyalgia","Neurologic Disorder","2025-09-02",{"date":417,"type":48},"2025-09-09",{"date":419,"type":48},"2025-07-23",{"date":322,"type":23},{"name":54,"class":55},{"id":423,"slug":424,"hasResults":12,"nctId":425,"briefTitle":426,"officialTitle":426,"acronym":4,"eligibilityCriteria":427,"healthyVolunteers":203,"sex":18,"minAge":19,"maxAge":158,"enrollmentInfo":428,"targetDuration":4,"studyType":24,"phases":429,"briefSummary":430,"conditions":431,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":84},"100597684","wim-exosuit-wearable-soft-robot-for-enhancing-walking-activity-100597684","NCT07061691","WIM Exosuit Wearable Soft Robot for Enhancing Walking Activity","Inclusion Criteria:\n\n* \\- Be at least 6 months post-stroke, have a diagnosis of Parkinson's, have a diagnosis of multiple sclerosis, or an adult older than 65 with no known neurological diagnoses.\n\nFor the Optimization Aim of the study, Participants may also be healthy individuals with no known impairments.\n\n* Age: 18-89 years of age\n* For stroke, Parkinson's, multiple sclerosis, or older adult participants, must have adequate cognitive function (MMSE score \\>17)\n* Ability to walk at least 10 meters with maximum of 1 person assist\n* Able to safely fit into the WIM exosuit, which is confirmed via an in-person fitting..\n\nExclusion Criteria:\n\n* \\- \\\u003C90 days post major orthopedic surgery (i.e. hip, knee, and\u002For ankle joint replacement.)\n* \\\u003C 6 months post CABG or cardiac valve procedure\n* Any skin irritations \u002F conditions that may preclude a participant from tolerating the use of the exosuit.\n* Severe osteoporosis, defined as osteoporosis that has been diagnosed and a participant's doctor has recommended pharmacologic treatment, or there is both a history of osteoporosis and a history of fractures.\n* Serious cardiac conditions, such as hospitalization for myocardial infarction or heart surgery within 3 months, history of congestive heart failure, documented serious and unstable cardiac arrhythmias, hypertrophic cardiomyopathy, severe aortic stenosis, angina or dyspnea at rest or during activities of daily living.\n* Pregnancy\n* Uncontrolled hypertension (resting systolic blood pressure greater than or equal to 150, or resting diastolic pressure greater than or equal to 90.) If a participant demonstrates a BP greater than these values, then the participant will sit quietly for 5 mins, and then be re-checked. If the BP values remain over those thresholds, then the participant will be excluded. Individuals in such situations may return to be re-screened for participation after they follow up with their physician and the hypertension is better controlled.\n* Lower extremity fracture, either currently or within the past 6 months.\n* Modified Ashworth Spasticity (MAS) scores of ≥ 3 in hip flexors or extensors, if the participant is post-stroke or multiple sclerosis.\n* Pre-existing neurological disorders such as amyotrophic lateral sclerosis (ALS), dementia\n* History of major head trauma, lower extremity amputation, non-healing ulcers of a lower extremity, ongoing active infections, legal blindness, or a history of significant psychiatric illness.",{"count":385,"type":23},[26],"This study is to develop, test, and optimize a soft hip wearable robot for individuals who have experience a stroke.",[142,432],"Healthy","2025-08-22",{"date":435,"type":48},"2025-08-29",{"date":437,"type":48},"2025-07-07",{"date":439,"type":23},"2028-07",{"name":54,"class":55},{"id":442,"slug":443,"hasResults":12,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":4,"eligibilityCriteria":447,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":448,"targetDuration":4,"studyType":24,"phases":450,"briefSummary":451,"conditions":452,"keywords":454,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":458,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":84},"100589144","transcutaneous-electrical-stimulation-for-stroke-patients-100589144","NCT06950593","Transcutaneous Electrical Stimulation for Stroke Patients","Upper Limb Function Following Transcutaneous Electrical Spinal Cord Stimulation in Individuals With Hemiplegic Stroke","Inclusion Criteria:\n\n* 18 years or older\n* able and willing to give written consent and comply with study procedures\n* at least 6 months post-stroke\n* hemiplegia secondary to stroke\n* UE Fugle Meyer Assessment \\\u003C35\n* not currently receiving regular occupational therapy services\n* participant has received clearance from physician to participate in study\n* participant has at least a rudimentary comprehension of English\n\nExclusion Criteria:\n\n* botox injection in upper extremity within the last 4 months\n* modified ashworth score of 4 in any joint of the affected limb\n* pregnant or nursing\n* using a powered, implanted cardiac device for monitoring or support of heart function (i.e. pacemaker, defibrillator, or LVAD), or anti-spasticity implantable pumps, or cochlear implants\n* unhealed bone fractures\n* severe contractures in the upper extremities\n* active cancer or cancer remission less than 5 years\n* orthopedic dysfunction, injury, or surgery that would impact the individual's ability to use the upper extremities\n* recent procedure or operation of the spinal cord within the past year\n* traumatic brain injury or neurological conditions that would impact the study\n* skull fracture that has developed within the past 6 months\n* non-English speakers",{"count":449,"type":23},14,[26],"This study aims to evaluate the feasibility and impact of transcutaneous electrical stimulation of the spinal cord (TESS) on the recovery of post-stroke individuals who have upper limb hemiparesis. It will compare outcomes measures between individuals who receive upper limb task specific training with TESS and individuals who receive task specific training of the upper limb with Sham, or fake, TESS.",[453],"Upper Limb Hemiparesis Following Stroke",[455,456,457],"upper limb hemiparesis","stroke","transcutaneous spinal cord stimulation (TESS)","2025-08-07",{"date":460,"type":48},"2025-08-12",{"date":462,"type":23},"2025-08-18",{"date":464,"type":23},"2027-01-01",{"name":54,"class":55},{"id":467,"slug":468,"hasResults":12,"nctId":469,"briefTitle":470,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":203,"sex":18,"minAge":19,"maxAge":472,"enrollmentInfo":473,"targetDuration":4,"studyType":24,"phases":474,"briefSummary":476,"conditions":477,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":478,"lastUpdatePostDateStruct":479,"startDateStruct":481,"completionDateStruct":483,"leadSponsor":485,"locationsCount":4},"100592882","early-phase-1-lower-limb-exonet-development-and-evaluation-for-gait-assistance-with-stroke-survivors-100592882","NCT06999213","Lower Limb ExoNET: Development and Evaluation for Gait Assistance With Stroke Survivors","Inclusion Criteria:\n\n* Age 18-70 years old\n* Ability to provide informed consent\n* Capable of ambulating without the use of assistive devices for 2 hours\n\nExclusion Criteria:\n\n* History of stroke, SCI, or other neurological medical diagnoses\n* Pregnant\n* Severe medical diagnoses (e.g. cardiovascular, orthopedic)\n* Skin allergies or irritation; open wounds\n* Prisoners\n* Cognitively impaired adults","70 Years",{"count":385,"type":23},[475],"EARLY_PHASE1","Stroke-related gait impairments, such as poor limb coordination, imbalance, and reduced push-off strength, are often addressed using robotic systems or electrical stimulation, which can be costly, invasive, or insufficient for long-term recovery. Current devices often assist movement but fail to promote functional motor learning. Research supports rehabilitation strategies that amplify gait errors to drive neuroplasticity and adaptation. The LegExoNET (Exoskeletal Network for Elastic Torque) is a novel, passive wearable exoskeleton designed to address this need by enabling both assistive and therapeutic gait training. It stores and releases elastic energy to aid movement while allowing natural joint motion. The system aims to support individuals post-stroke transitioning to independent rehabilitation by offering a lightweight, affordable, and adaptive solution. Initial testing will focus on healthy individuals to assess safety and feasibility before expanding to stroke populations. The LegExoNET has the potential to enhance gait recovery and reduce therapist burden through error augmentation and personalized support, both in clinical and at-home settings.",[432],"2025-07-28",{"date":480,"type":48},"2025-07-30",{"date":482,"type":23},"2026-01-31",{"date":484,"type":23},"2029-12-31",{"name":54,"class":55},{"id":487,"slug":488,"hasResults":12,"nctId":489,"briefTitle":490,"officialTitle":491,"acronym":4,"eligibilityCriteria":492,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":472,"enrollmentInfo":493,"targetDuration":4,"studyType":24,"phases":495,"briefSummary":496,"conditions":497,"keywords":502,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":504,"lastUpdatePostDateStruct":505,"startDateStruct":507,"completionDateStruct":509,"leadSponsor":511,"locationsCount":84},"100595461","neuromusculoskeletal-interface-for-bionic-arms-100595461","NCT07032753","Neuromusculoskeletal Interface for Bionic Arms","Neuromusculoskeletal Interface for Bionic Arms: A Randomized Crossover Study","Inclusion Criteria:\n\n* Between the ages of 18 and 70 years old\n* Unilateral transhumeral level absence\n* Candidate for a myoelectric prosthesis (can generate mV level electromyographic EMG signals as detected by surface electrodes).\n* Candidate for TMR surgery as verified by surgical team\n* Candidate for OPRA surgery as verified by surgical team\n* English speaking\n\nExclusion Criteria:\n\n* Significant new injury that would prevent use of a prosthesis: The ability to consistently wear a prosthesis and perform activities of daily living and specific performance tasks is necessary to evaluate the relative benefits of the interventions.\n* Cognitive impairment sufficient to adversely affect understanding of, or compliance with, study requirements, ability to communicate experiences, or ability to give informed consent: The ability to understand and comply with requirements of the study is essential in order for the study to generate usable, reliable data. The ability to obtain relevant user feedback through questionnaires and informal discussion adds significant value to this study. These cognitive impairments would be confirmed with the Mini-Mental State exam.\n* Proximal nerve injury that would prevent TMR or sensory feedback\n* Significant other comorbidity: Any other medical issues or injuries that would preclude completion of the study, use of the prostheses, or that would otherwise prevent acquisition of useable data by researchers. Examples include: injuries to the shoulder, cervical spine or sound side joint pain that would prohibit the participants from being able use a prosthesis. Medical conditions including unregulated high blood pressure or advanced heart disease that would exclude the participant as an appropriate surgical candidate.\n* Individuals who smoke. This may interfere with the OPRA process from both bone healing and soft tissue standpoints.\n* Individuals with active implants. This has been a restriction of prior FDA IDE to investigate e-OPRA.\n* Pregnant women\n* Non-English speaking",{"count":494,"type":23},12,[26],"The overall objective of this proposal is to perform a first-in-human home trial of the Electronic Osseoanchored Prostheses for the Rehabilitation of Amputees (e-OPRA) implant system in individuals with transhumeral amputations who have had Targeted Muscle Reinnervation (TMR) surgery and use a pattern recognition-controlled myoelectric prosthesis. The purpose of the study is to capture preliminary safety and effectiveness information on the e-OPRA device when used with the prosthetic systems. The investigators expect that the e-OPRA implant system will be safe and provide clinically and statistically significant improvements in control and comfort.\n\nSpecifically, the investigators hypothesize that the e-OPRA system will (1) allow for training of more functional prosthesis controllers, (2) provide more stable electromyographic (EMG) signals, reducing the need to recalibrate the prosthetic control system, and (3) be more comfortable, as it does not require a tethered arm-band to record surface EMG signals.\n\nPhase 1: Perform TMR and e-OPRA surgeries in 8 persons with transhumeral amputations.\n\nPhase 2: Perform a randomized cross-over study to compare the OPRA and e-OPRA system (without sensory feedback) in 8 transhumeral amputees who have received TMR.\n\nPhase 3: Perform a randomized cross-over study to compare the e-OPRA system with and without sensory feedback in 8 transhumeral amputees who have received TMR.",[498,499,500,501],"Amputation","Amputation, Traumatic","Amputation, Surgical","Upper Limb Amputation Above Elbow (Injury)",[503],"eOPRA for transhumeral amputees","2025-06-12",{"date":506,"type":48},"2025-06-24",{"date":508,"type":23},"2026-01-01",{"date":510,"type":23},"2029-05-31",{"name":54,"class":55},{"id":513,"slug":514,"hasResults":12,"nctId":515,"briefTitle":516,"officialTitle":517,"acronym":4,"eligibilityCriteria":518,"healthyVolunteers":12,"sex":18,"minAge":116,"maxAge":519,"enrollmentInfo":520,"targetDuration":4,"studyType":24,"phases":522,"briefSummary":523,"conditions":524,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":527,"startDateStruct":529,"completionDateStruct":531,"leadSponsor":532,"locationsCount":84},"100501142","neuromuscular-mechanisms-of-specific-trunk-interventions-in-children-with-cp-100501142","NCT05805410","Neuromuscular Mechanisms of Specific Trunk Interventions in Children With CP","Neuromuscular Mechanisms of Specific Trunk Interventions in Children With Cerebral Palsy","Inclusion Criteria:\n\n* Children with a diagnosis of bilateral spastic CP attributed to complications of prematurity, intracranial hemorrhage and periventricular leukmalacia according to the definition of Bax.\n* Children aged 4 to 12 years old without Botulinum toxin treatment within 6 months, and without surgeries (such as selective dorsal rhizotomy) within 12 months before the onset of the training.\n* Subjects will be able to remain seated without help for ≥10s.\n* GMFCS levels will be I to IV.\n* Children must be able to signal pain, fear or discomfort reliably.\n* Children with mild scoliosis (Cobb angle \\\u003C 20 °).\n* Children with CP who have no prior hippotherapy experiences within 6 months.\n\nExclusion Criteria:\n\n* severe lower extremity contractures, fractures, osseous instabilities, osteoporosis.\n* severe disproportional bone growth.\n* unhealed skin lesions in the lower extremities.\n* thromboembolic diseases, cardiovascular instability.\n* aggressive or self-harming behaviors.","12 Years",{"count":521,"type":23},44,[26],"Determine the effect of repeated pelvis perturbation training on trunk posture and locomotor function in children with CP.",[525],"Child Behavior","2025-05-28",{"date":528,"type":48},"2025-06-03",{"date":530,"type":48},"2022-11-01",{"date":250,"type":23},{"name":54,"class":55},{"id":534,"slug":535,"hasResults":12,"nctId":536,"briefTitle":537,"officialTitle":537,"acronym":4,"eligibilityCriteria":538,"healthyVolunteers":12,"sex":18,"minAge":539,"maxAge":20,"enrollmentInfo":540,"targetDuration":4,"studyType":24,"phases":541,"briefSummary":542,"conditions":543,"keywords":544,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":546,"startDateStruct":547,"completionDateStruct":549,"leadSponsor":551,"locationsCount":84},"100306056","constraint-induced-movement-therapy-for-walking-in-individuals-post-stroke-100306056","NCT03264261","Constraint Induced Movement Therapy for Walking in Individuals Post Stroke","Inclusion Criteria:\n\n1. age between 21 and 75 years;\n2. history of unilateral, supratentorial, ischemic or hemorrhagic stroke;\n3. no prior stroke;\n4. demonstration of impaired walking function (self-selected walking speed ≤ 0.80 m\u002Fs);\n5. able to stand and walk (\\>10 meters) without physical assistance.\n\nExclusion Criteria:\n\n1. significant cardiorespiratory\u002Fmetabolic disease;\n2. other neurological or orthopedic injury that impairs locomotion;\n3. scores on the Mini Mental Status examination \\\u003C 24;\n4. stroke of the brainstem or cerebellar lesions;\n5. uncontrolled hypertension (systolic \\> 200 mm Hg, diastolic \\> 110 mm Hg);\n6. botox injection within 6 months of starting the study.","21 Years",{"count":160,"type":23},[26],"To compare the effect of constraint induced movement therapy (CIMT) vs. treadmill training only on walking function in individuals post-stroke, a 6 week, single-blind, randomized training study will be conducted with three assessments of gait to determine the training effect. Subjects will be randomized to either the CIMT or treadmill training only groups at the initial test. Following the initial test, individuals from the 2 groups will undergo intensive locomotor training. Training will be performed 3 times per week for 6 weeks with the training time for each visit set to 45 minutes as tolerated. Data collection will proceed until 36 subjects from 2 groups have been trained.",[142],[545],"stroke, locomotion",{"date":528,"type":48},{"date":548,"type":48},"2017-08-14",{"date":550,"type":23},"2025-12-30",{"name":54,"class":55},{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":556,"acronym":4,"eligibilityCriteria":557,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":558,"enrollmentInfo":559,"targetDuration":4,"studyType":24,"phases":561,"briefSummary":562,"conditions":563,"keywords":4,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":526,"lastUpdatePostDateStruct":564,"startDateStruct":565,"completionDateStruct":567,"leadSponsor":568,"locationsCount":84},"100285101","improve-dynamic-lateral-balance-of-humans-with-sci-100285101","NCT02991248","Improve Dynamic Lateral Balance of Humans With SCI","Inclusion Criteria:\n\n1. age between 18 and 65 years;\n2. medically stable with medical clearance to participate;\n3. level of the SCI lesion between C4-T10;\n4. passive range of motion of the legs within functional limits of ambulation;\n5. ability to walk on a treadmill for more than 20 minutes with partial body weight support as needed and short sitting\u002Fstanding breaks;\n6. ability to ambulate without orthotics or with orthotics that do not cross the knee for more than 10 meters\n\nExclusion Criteria:\n\n1. the presence of unhealed decubiti, existing infection, severe cardiovascular and pulmonary disease, concomitant central or peripheral neurological injury (e.g. traumatic head injury or peripheral nerve damage in lower limbs);\n2. history of recurrent fractures and\u002For known orthopedic injury to the lower extremities;\n3. Botox injection within 6 months of starting the study, and current receiving physical therapy treatment;\n4. have metallic implantation in the spinal region underneath where electrodes may be placed.","65 Years",{"count":560,"type":23},54,[26],"This study is to test whether pelvis perturbation training paired with transcutaneous spinal direct current stimulation (tsDCS) will be effective in improving dynamic balance and locomotor function in humans with SCI. One group will receive pelvis perturbation training paired with tsDCS, one group will receive pelvis perturbation training paired with sham, and one group will receive treadmill training only.",[208],{"date":528,"type":48},{"date":566,"type":48},"2018-11-01",{"date":550,"type":23},{"name":54,"class":55},{"id":570,"slug":571,"hasResults":12,"nctId":572,"briefTitle":573,"officialTitle":574,"acronym":4,"eligibilityCriteria":575,"healthyVolunteers":203,"sex":18,"minAge":19,"maxAge":182,"enrollmentInfo":576,"targetDuration":4,"studyType":235,"phases":4,"briefSummary":577,"conditions":578,"keywords":579,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":586,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":84},"100547670","evaluation-of-sensorimotor-ankle-impairments-in-chronic-stroke-100547670","NCT06410989","Evaluation of Sensorimotor Ankle Impairments in Chronic Stroke","Relating Ankle Impairments to Walking Ability for Characterization of Sensorimotor Function in Individuals With Chronic Stroke","Inclusion criteria\n\n* 40 - 80 years of age, inclusive\n* Normal hearing and vision, can be corrected\n* No skin allergies to adhesive material, conductive paste, or silver\n* Ability to walk \\>10m independently on level ground without an assistive device or bracing\n* Able to understand and give informed consent\n* Able to understand and speak English\n\nInclusion criteria specific for healthy participants:\n\n* No neurological disorders\n* Absence of pathology that could cause abnormal movements of extremities (e.g., epilepsy, stroke, marked arthritis, chronic pain, musculoskeletal injuries)\n\nInclusion criteria specific for participants post-stroke:\n\n* Unilateral, supratentorial ischemic or hemorrhagic stroke ≥ six months prior\n* Minimum activation against gravity for dorsiflexion and plantarflexion, equivalent to a Manual Muscle Test (MMT) score of ≥ +2\n* Self-selected walking speed is less than 1.2 m\u002Fs\n\nExclusion criteria\n\n* Cognitive limitations that would prevent playing games\n* Adults unable to consent, pregnant women, children, or prisoners\n* Infection, wounds, or graft sites on lower limbs\n* History of sustained non-prescribed drug use or substance abuse (as reported by subject; current nicotine use is allowed)\n* History of peripheral nerve injury\n* Severe hip, knee, or ankle arthritis\n* Recent fracture or osteoporosis (as reported by subject)\n* Bone or joint instability in the lower limb\n* Severe pain syndromes affecting any part of the lower limbs\n* Fixed contractures affecting the lower limbs\n* Medical (cardiac, renal, hepatic, oncological) or psychiatric disease that would interfere with study procedures\n* Inability or unwillingness to perform study-required activities\n* Prior neurosurgical procedures\n\nExclusion criteria specific for healthy participants:\n\n\\- Any neurological diseases (e.g., stroke, Parkinson's disease or other neurodegenerative disorder, severe dementia, brain injury, spinal cord injury, multiple sclerosis, or cancer of the central nervous system)\n\nExclusion criteria specific for participants post-stroke:\n\n* Co-existence of other neurological diseases (e.g., Parkinson's disease or other neurodegenerative disorder, severe dementia, brain injury, spinal cord injury, multiple sclerosis, or cancer of the central nervous system)\n* Botox (botulinum toxin) injection to lower limbs within the prior 3 months\n* Significant spasticity or contracture in the lower limbs (Modified Ashworth Scale score of 4)\n* Severe aphasia\n* Significant loss of sensation in the lower limbs",{"count":118,"type":23},"The purpose of this study is to capture sensorimotor ankle function in a chronic stroke population through validation of novel, experimental metrics and their comparison with established, clinical measures of function. For this purpose, the researchers will evaluate various single-joint, impairment-level measures such as visuomotor tracking performance and proprioception as well as functional-level measures including spatiotemporal gait (e.g., gait speed and stride length\u002Ftime) and standardized clinical scales. This study will be carried out in chronic stroke patients as well as age-matched healthy controls. Results will help the researchers identify more quantitative metrics that can be used to monitor and rehabilitate sensorimotor function following stroke.",[142],[580,581,582,583,584],"Robotic Rehabilitation","Sensorimotor function","Proprioception","Motor Control","Ankle Rehabilitation","2025-05-21",{"date":587,"type":48},"2025-05-25",{"date":589,"type":23},"2025-07-15",{"date":591,"type":23},"2027-08-31",{"name":54,"class":55},{"id":594,"slug":595,"hasResults":12,"nctId":596,"briefTitle":597,"officialTitle":597,"acronym":598,"eligibilityCriteria":599,"healthyVolunteers":203,"sex":18,"minAge":19,"maxAge":182,"enrollmentInfo":600,"targetDuration":4,"studyType":24,"phases":602,"briefSummary":603,"conditions":604,"keywords":605,"overallStatus":76,"whyStopped":4,"lastUpdateSubmitDate":585,"lastUpdatePostDateStruct":611,"startDateStruct":612,"completionDateStruct":614,"leadSponsor":616,"locationsCount":84},"100406918","human-like-robotic-controllers-for-enhanced-motor-learning-100406918","NCT04578665","Human-like Robotic Controllers for Enhanced Motor Learning","HRCEML","Inclusion Criteria for Healthy Participants:\n\n* Age from 18 to 80 years\n* No history of a brain and\u002For skull lesion\n* Normal hearing and vision, can be corrected\n* Able to understand and give informed consent\n* No neurological disorders\n* Absence of pathology that could cause abnormal movements of extremities (e.g., epilepsy, stroke, marked arthritis, chronic pain, musculoskeletal injuries)\n* Able to understand and speak English\n* Height between 3 foot 6 inches (1.1 meters) and 6 foot 2 inches\n\nInclusion Criteria for Participants Post-Stroke:\n\n* Age from 18 to 80 years\n* History of unilateral, supratentorial, ischemic or hemorrhage stroke greater than 6 month\n* Ability to walk \\>10m independently on level ground, allowed to use assistive devices or bracing as needed\n* Self-selected walking speed is less than 0.8 meters\u002Fsec\n* Medically stable\n* No concurrent surgeries, medical treatments, participation in research or outpatient therapy\n* Normal hearing and vision, both can be corrected\n* Able to understand and give informed consent\n* Able to understand and speak English\n* Height between 3 foot 6 inches (1.1 meters) and 6 foot 2 inches\n\nInclusion Criteria for Participants with Spinal Cord Injury:\n\n* Age from 18 to 80 years\n* History of incomplete SCI injury (ASIA C or D) \\> 6 months prior\n* Ability to walk \\>10 m independently on level ground, allowed to use assistive devices or bracing as needed\n* Self-selected walking speed is less than 0.8 meters\u002Fsec\n* Medically stable\n* No concurrent surgeries, medical treatments, participation in research or outpatient therapy\n* Normal hearing and vision, both can be corrected\n* Able to understand and give informed consent\n* Able to understand and speak English\n* Height between 3 foot 6 inches (1.1 meters) and 6 foot 2 inches\n\nExclusion Criteria for Healthy Participants:\n\n* Weight over 220 lbs\n* Pregnancy (ruled out by pregnancy questionnaire)\n* Current presence of wounds or pressure ulcers\n* Multiple sclerosis, Parkinson's disease or other neurodegenerative disorder, severe dementia, brain injury, spinal cord injury, or cancer of the central nervous system\n* History of significant head trauma (i.e., extended loss of consciousness, neurological sequelae)\n* Known structural brain lesion\n* Significant other disease (heart disease, malignant tumors, mental disorders)\n* History or peripheral nerve injury\n* History of sustained non-prescribed drug use or substance abuse (exception: current nicotine use is allowed)\n* Prior neurosurgical procedures\n* Inability or unwillingness to perform study-required activities\n* Prisoners\n* Unable to meet SRAlab \"MRI Pre-Examination Screening Form\" requirements\n\nExclusion Criteria for Participants Post-Stroke:\n\n* Weight over 220 lbs\n* Pregnancy (ruled out by pregnancy test)\n* Botox (botulinum toxin) injection to lower limbs within the prior 3 months, or planned injection during study period.\n* Current presence of wounds or pressure ulcers\n* History of sustained non-prescribed drug use or substance abuse (exception: current nicotine use is allowed)\n* Reduced cognitive function\n* Severe aphasia\n* Prisoners\n* Co-existence of other neurological diseases (e.g., Parkinson's disease or other neurodegenerative disorder, severe dementia, brain injury, spinal cord injury, multiple sclerosis, or cancer of the central nervous system)\n* History or peripheral nerve injury\n* Severe hip, knee, or ankle arthritis\n* Recent fracture or osteoporosis\n* Significant spasticity in the lower limbs (≥3 on Modified Ashworth Scale)\n* Medical (cardiac, renal, hepatic, oncological) or psychiatric disease that would interfere with study procedures\n* Inability or unwillingness to perform study-required activities\n* Unable to meet SRAlab \"MRI Pre-Examination Screening Form\" requirements\n\nExclusion Criteria for Participants with Spinal Cord Injury:\n\n* Weight over 220 lbs\n* Pregnancy (ruled out by pregnancy test)\n* Botox (botulinum toxin) injection to lower limbs within the prior 3 months, or planned injection during study period\n* Current presence of wounds or pressure ulcers\n* History of sustained non-prescribed drug use or substance abuse (exception: current nicotine use is allowed)\n* Prisoners\n* Co-existence of other neurological diseases (e.g., Parkinson's disease or other neurodegenerative disorder, severe dementia, brain injury, spinal cord injury, multiple sclerosis, or cancer of the central nervous system)\n* History of peripheral nerve injury\n* Severe hip, knee, or ankle arthritis\n* Recent fracture or osteoporosis\n* Significant spasticity in the lower limbs ( ≥3 on Modified Ashworth Scale)\n* Medical (cardiac, renal, hepatic, oncological) or psychiatric disease that would interfere with study procedures\n* Inability or unwillingness to perform study-required activities\n* Unable to meet SRAlab \"MRI Pre-Examination Screening Form\" requirements",{"count":601,"type":23},764,[26],"The purpose of this study is to develop a new paradigm to understand how humans physically interact with each other at a single and at multiple joints, with multiple contact points, so as to synthesize robot controllers that can exhibit human-like behavior when interacting with humans (e.g., exoskeleton) or other co-robots. The investigators will develop models for a single joint robot (i.e. at the ankle joint) that can vary its haptic behavioral interactions at variable impedances, and replicate in a multi-joint robot (i.e. at the ankle, knee, and hip joints). The investigators will collect data from healthy participants and clinical populations to create a controller based on our models to implement in the robots. Then, the investigators will test our models via the robots to investigate the mechanisms underlying enhanced motor learning during different human-human haptic interaction behaviors (i.e. collaboration, competition, and cooperation. This study will be carried out in healthy participants, participants post-stroke, and participants with spinal cord injury (SCI).",[142,166],[142,166,580,606,607,608,609,610],"Electromyography","Haptic Feedback","Dyad","Skill Level","Impedance",{"date":587,"type":48},{"date":613,"type":48},"2021-07-13",{"date":615,"type":23},"2025-12",{"name":54,"class":55},""]